1.85 USD
▼-0.11-5.61%
盘后 1.87 +1.08%
2026-09-15
市值
$329.56M
市盈率
—
EPS
-0.40
股息率
—
52 周区间
1.61 – 6.88
成交量
2.44M
Beta
0.84
目标价
8.92
52W 低 1.6152W 高 6.88
价格走势
公司简介
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company’s lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization. It also develops CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; C...